PLoS medicine
-
The recommendations in several countries to stop using the ChAdOx1 vaccine has led to vaccine programs combining different Coronavirus Disease 2019 (COVID-19) vaccine types, which necessitates knowledge on vaccine effectiveness (VE) of heterologous vaccine schedules. The aim of this Danish nationwide population-based cohort study was therefore to estimate the VE against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and death following the first dose of the ChAdOx1 vaccine and the combination of the ChAdOx1/mRNA vaccines. ⋯ In this study, we observed a large reduction in the risk of SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine, compared with unvaccinated individuals.
-
We have a new and unprecedented opportunity to mitigate the suffering, death and inequities of COVID-19 in the United States with vaccine boosters-if we deploy them effectively, rapidly, and widely with simplified messaging to all eligible adults.
-
[This corrects the article DOI: 10.1371/journal.pmed.1003732.].